设计一种口服可生物利用的小分子,该分子调节微管关联蛋白的mRNA前分离
Peiyuan Zhang1, Amirhossein Taghavi2, Masahito Abe1
1Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.
ACS chemical biology
|June 23, 2025
概括
研究人员开发了一种针对RNA的小分子,用于治疗与17号染色体 (FTDP-17) 相关的帕金森症前性痴呆症. 这种分子通过稳定一个关键的RNA结构来降低有毒的4R蛋白,显示出口服和脑透的前景.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 与染色体17 (FTDP-17) 相关的前性痴呆与帕金森症与MAPT基因的异常拼接有关,导致有毒的4R蛋白积累.
- 目前对FTDP-17的治疗策略有限,这突显了针对潜在分子机制的新型治疗方法的需要.
研究的目的:
- 设计和表征一种能够调节MAPT前mRNA拼接的RNA向小分子.
- 为了减少对MAPT前mRNA中的exon10的包含,从而减少有毒4R tau蛋白的产生.
- 在FTDP-17.7的细胞和动物模型中评估设计分子的治疗潜力.
主要方法:
- 使用结构导向药物设计,创建针对MAPT前mRNA中的特定调节元件的小分子.
- 实验室和细胞测试用于确认化合物与RNA标结合,并评估其对mRNA前拼接的影响.
- 活体研究涉及将该化合物口服给人类tau (htau) 敲入小鼠模型,以评估其疗效和药物动力学特性.
主要成果:
- 设计的小分子证明了与向RNA结构的特定结合,并有效地减少了在包括初级神经元在内的各种细胞模型中的第10个外的包含.
- 在Htau小鼠中,口服该化合物导致4R tau蛋白水平降低,缓解细胞病理,改善行为缺陷.
- 该化合物表现出口服生物利用性和血脑屏障的透性,这表明它有治疗神经系统疾病的潜力.
结论:
- 这项研究介绍了一种新的RNA向小分子,它成功调节异常的tau拼接,为FTDP-17.提供了潜在的治疗策略.
- 这些发现表明,设计具有口服生物可用性和中枢神经系统透性的RNA向化合物的可行管道,用于治疗神经退行性疾病.
- 开发的分子有效地减少了有毒的tau物种,并在相关的动物模型中改善了疾病表型,为进一步的临床开发铺平了道路.
相关概念视频
01:32RNA Splicing
57.2K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.2K
02:01pre-mRNA Processing
53.6K
In eukaryotic cells, transcripts made by RNA polymerase are modified and processed before exiting the nucleus. Unprocessed RNA is called precursor mRNA or pre-mRNA to distinguish it from mature mRNA.
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
53.6K
02:18Alternative RNA Splicing
21.8K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.8K